CRO/Sponsor

What you need to know to save the bottom line...and your sanity.

Target Health and Infacare used a CRF database to answer all of FDA's questions.

A new paradigm that could transform a drug failure into a drug success would narrow the target population to those patients most likely to benefit from such treatment.

Certain clinical project metrics are heavily influenced by country-specific regulations or conditions, such as IEC review times.

A delay in receiving one piece of information may have a severe impact on later parts of the process, such as label text.

The Declaration of Helsinki requires that control groups receive the “best” current treatment, not the “local” one. This shift in wording has profound implications.

Our training places heavy emphasis on site selection: The entire study may suffer if sites are chosen poorly.

The CRO industry is on a course for continued rapid growth with the rise of genetics and genomics, as well as the push toward partnering and more postapproval research.

The idea for this ACT CRO Retrospective came from the first SoCRA meeting I attended in 2003, just as I took over the position of Editor-In-Chief. I had the good fortune to hear PRA International's President and CEO, Patrick K. Donnelly speak about the CRO industry, and I was inspired by what he had to say. The CRO industry has exploded over the last 12 years. It has endured growing pains and it continues to develop. Therefore what better time than now to hear from the thought leaders who have been involved in the transformation taking place.